公开(公告)号：US20220308073A1

公开(公告)日：2022-09-29

申请号：US17827933

申请日：2022-05-30

Applicant: PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY ,  NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY

Inventor： Makoto Michikawa ,  Hiroyasu Akatsu ,  Mohammad Abdullah ,  Etsuro Matsubara ,  Noriyuki Kimura

IPC: G01N33/68

Abstract: An object of the present invention is to provide a marker useful for early diagnosis and differentiation of Alzheimer's disease, and use thereof. An Alzheimer's disease biomarker composed of blood flotillin is provided.

公开(公告)号：US20220194942A1

公开(公告)日：2022-06-23

申请号：US17679075

申请日：2022-02-23

Applicant: Oita University Institute of Advanced Medicine, Inc.

Inventor： Hiroyuki Kouji ,  Kentaro Yamada ,  Akira Katoh ,  Toshimasa Ishizaki ,  Shigeru Matsuoka ,  Akira Nishizono ,  Tadashi Mishina ,  Atsushi Yoshimori

IPC: C07D471/18 ,  A61P31/14 ,  A61P35/00 ,  C07D471/08

Abstract: The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIIF or formula XXIIB: wherein R1, R2A, R2B, R3, and R4 are defined in the specification, a solvent, or a pharmaceutically acceptable salt thereof, use of such a compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prophylaxis of rabies and cancer, a pharmaceutical composition comprising such a compound, solvate, or pharmaceutically acceptable salt thereof, and a method for the treatment or prophylaxis of rabies and cancer using the same.

公开(公告)号：US20200224365A1

公开(公告)日：2020-07-16

申请号：US16649108

申请日：2018-03-12

Applicant: NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY

Inventor： Taro KINUMOTO

IPC: D21B1/02 ,  D21H11/12 ,  D21B1/06

Abstract: The present invention provides: a cellulose nanofiber enabling the provision of a high-performance sheet-like material; a method for producing the cellulose nanofiber; and a sheet-like material obtained from the cellulose nanofiber. A bamboo-derived cellulose nanofiber having a cellulose purity of at least 90%, a fiber diameter of 10-20 nm, and a crystallinity of at least 70% can be obtained by a method comprising: (1) a step for subjecting a bamboo material to an alkali treatment and a mechanical treatment to prepare bamboo fibers; (2) a step for delignificating the obtained bamboo fibers; (3) a step for mechanically spreading the delignificated bamboo fibers; (4) a step for removing hemicellulose from the spread bamboo fibers; and (5) a step for removing metal components from the bamboo fibers from which hemicellulose has been removed. A high strength sheet material having a tensile strength of 7-200 N for a basis weight of 10-210 g/m2 or a high strength sheet material having a tensile strength of 7-200 N for a density of 0.3-1.1 g/cm3 can be obtained by making this cellulose nanofiber into a sheet.

公开(公告)号：US20170259247A1

公开(公告)日：2017-09-14

申请号：US15510095

申请日：2015-09-09

Applicant: Kyoto University ,  OITA UNIVERSITY ,  KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

Inventor： Hiroshi KITAGAWA ,  Kohei KUSADA ,  Hirokazu KOBAYASHI ,  Katsutoshi NAGAOKA ,  Katsutoshi SATO ,  Syo MATSUMURA ,  Tomokazu YAMAMOTO

IPC: B01J23/46 ,  F01N3/28 ,  C22C1/04 ,  C22C5/04 ,  B01J37/16 ,  B22F9/24

CPC classification number: B01J23/462 ,  B01J23/46 ,  B01J37/16 ,  B22F1/00 ,  B22F9/24 ,  B22F2009/245 ,  B22F2301/25 ,  B22F2998/10 ,  C22C1/0466 ,  C22C5/02 ,  C22C5/04 ,  C22C5/06 ,  F01N3/10 ,  F01N3/28

Abstract: The present invention provides an alloy fine particle including palladium and ruthenium, the alloy fine particle including at least one first phase in which the palladium is more abundant than the ruthenium and at least one second phase in which the ruthenium is more abundant than the palladium, the at least one first phase and the at least one second phase being separated by a phase boundary, the palladium and the ruthenium being distributed in the phase boundary in such a manner that the molar ratio of the palladium and the ruthenium continually changes, a plurality of crystalline structures being present together in the phase boundary.

公开(公告)号：US20150229012A1

公开(公告)日：2015-08-13

申请号：US14426918

申请日：2013-09-09

Applicant: NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY ,  TOYOTA JIDOSHA KABUSHIKI KAISHA

Inventor： Masahiro Toyoda ,  Hirofumi Iisaka

IPC: H01M12/08 ,  H01M4/583 ,  H01M4/38

CPC classification number: H01M12/08 ,  D01F11/122 ,  D01F11/129 ,  H01M4/382 ,  H01M4/583 ,  H01M4/96 ,  Y02E60/128 ,  Y10T428/2918

Abstract: The present invention is to provide a carbonaceous material for the air electrode of an air battery, which has more oxygen reduction reaction initiating points than conventional carbonaceous materials, and an air battery including the carbonaceous material. Presented is a carbonaceous material for use in an air electrode of an air battery, wherein an average aspect ratio of the carbonaceous material is 1 or more and less than 10, and an edge area of a surface of the carbonaceous material is 55 m2/g or more.

Abstract translation: 本发明提供一种空气电池的空气电极用碳质材料，其具有比常规含碳材料更多的氧还原反应起始点，以及含有碳质材料的空气电池。 本发明提供一种用于空气电池的空气电极的碳质材料，其中碳质材料的平均纵横比为1以上且小于10，碳质材料的表面的边缘面积为55m 2 / g 或者更多。

公开(公告)号：US20150022165A1

公开(公告)日：2015-01-22

申请号：US14372241

申请日：2012-07-19

Applicant: Oita University

Inventor： Terukazu Sato

IPC: H03K3/017 ,  H02M3/158

CPC classification number: H03K3/017 ,  H02M3/156 ,  H02M3/158 ,  H02M2001/0025

Abstract: A problem of the present invention is to provide a switching power supply device and a pulse width modulation circuit capable of operating stably in synchronization with a clock signal. To solve the problem, a pulse width modulation circuit 3A in a switching power supply device 1A includes square-wave voltage output means 8A for, when an integrated voltage Vn rises to an upper threshold voltage or more, shifting a square-wave voltage VPWM to L level, or when the voltage Vn drops to a lower threshold voltage or less, shifting the voltage VPWM to H level, and clock means 6A for outputting a first clock signal VCL1 and a second clock signal VCL2, which are 180° out of phase from each other. The square-wave voltage output means 8A is adapted to: (1) if the clock signal VCL1 changes while the voltage Vn is dropping, shift the voltage VPWM to H level even when the voltage Vn has not yet reached the lower threshold voltage; and (2) if the clock signal VCL2 changes while the voltage Vn is rising, shift the voltage VPWM to L level even when the voltage Vn has not yet reached the upper threshold voltage.

Abstract translation: 本发明的问题是提供一种与时钟信号同步地稳定地工作的开关电源装置和脉宽调制电路。 为了解决这个问题，开关电源装置1A中的脉冲宽度调制电路3A包括方波电压输出装置8A，当积分电压Vn上升到上限阈值以上时，将方波电压VPWM变换为 L电平，或者当电压Vn下降到较低的阈值电压或更小时，将电压VPWM移位到H电平;以及时钟装置6A，用于输出相位为180°的第一时钟信号VCL1和第二时钟信号VCL2 从彼此。 方波电压输出装置8A适于：（1）如果在电压Vn下降时时钟信号VCL1变化，即使电压Vn尚未达到较低的阈值电压，也将电压VPWM移动到H电平; 和（2）如果时钟信号VCL2在电压Vn升高时变化，即使当电压Vn尚未达到上限阈值电压时，也将电压VPWM移动到L电平。

公开(公告)号：US12208374B2

公开(公告)日：2025-01-28

申请号：US17909084

申请日：2021-03-05

Applicant: NISSAN CHEMICAL CORPORATION ,  NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY

Inventor： Taichi Nakazawa ,  Taro Kinumoto

IPC: B01J27/24 ,  B01J23/00 ,  B01J27/02 ,  B01J31/18

Abstract: When a metal catalyst is used as a catalyst in a catalyst layer of a polymer electrolyte fuel cell, improvement in catalytic activity and improvement in durability of the metal catalyst are intended. The catalyst composition of the present invention comprises a metal catalyst, a carbon material having a nitrogen-containing group on which the metal catalyst is carried, and an ionomer.

公开(公告)号：US20230390296A1

公开(公告)日：2023-12-07

申请号：US18250927

申请日：2021-10-29

Applicant: KEIO UNIVERSITY ,  OITA UNIVERSITY INSTITUTE OF ADVANCED MEDICINE, INC.

Inventor： Motoshi HAYANO ,  Hiroyuki KOUJI

IPC: A61K31/519 ,  A61K31/53 ,  A61K31/675 ,  A61P21/00

CPC classification number: A61K31/519 ,  A61K31/53 ,  A61K31/675 ,  A61P21/00

Abstract: The present disclosure has solved problems associated with the TGF-β family or the like, which is called Myostatin/GDF-8 as a molecular mechanism and targeted by sarcopenia, by evaluating a pharmaceutical product in physiological aging models, and in particular, by evaluating an increase in muscle mass and an increase in muscle strength; and has overcome harmful effects by applying targets of diseases different from sarcopenia such as dystrophia. The present disclosure has unexpectedly found a use for an OK-1-related compound as a sarcopenia treatment method through a pathway different from that of Wnt signal (proliferation of muscle stem cells) associated with Wnt/β-catenin inhibition, and is thus provided due to the findings.

公开(公告)号：US20220331300A1

公开(公告)日：2022-10-20

申请号：US17596101

申请日：2020-06-03

Applicant: OITA UNIVERSITY INSTITUTE OF ADVANCED MEDICINE, INC.

Inventor： Shigeru MATSUOKA ,  Akira KATOH ,  Tadashi MISHINA ,  Kentaro YAMADA ,  Atsushi YOSHIMORI ,  Toshimasa ISHIZAKI ,  Akira NISHIZONO ,  Hiroyuki KOUJI

IPC: A61K31/439 ,  A61P31/14

Abstract: The present disclosure provides compounds useful in the treatment and prevention of rabies. The present disclosure provides compounds represented by formula XXIF or XXIB [in the formulas, R1, R2A, R2B, R3, and R4 are as defined in the specification], solvates or pharmaceutically acceptable salts thereof, the use of these compounds, solvates or pharmaceutically acceptable salts thereof to treat or prevent rabies, pharmaceutical compositions including these compounds, solvates or pharmaceutically acceptable salts thereof, and a method for treating and preventing rabies using the same.

公开(公告)号：US20210214356A1

公开(公告)日：2021-07-15

申请号：US16791715

申请日：2020-02-14

Applicant: Oita University Institute of Advanced Medicine, Inc.

Inventor： Hiroyuki Kouji ,  Kentaro Yamada ,  Akira Kato ,  Toshimasa Ishizaki ,  Shigeru Matsuoka ,  Akira Nishizono ,  Tadashi Mishina ,  Atsushi Yoshimori

IPC: C07D471/18 ,  A61P31/14 ,  A61P35/00

Abstract: The present disclosure provides a compound that is useful for the treatment and prophylaxis of rabies. The present disclosure provides a compound represented by formula XXIF or formula XXIB: wherein R1, R2A, R2B, R3, and R4 are defined in the specification, a solvent, or a pharmaceutically acceptable salt thereof, use of such a compound, solvate, or pharmaceutically acceptable salt thereof for the treatment or prophylaxis of rabies and cancer, a pharmaceutical composition comprising such a compound, solvate, or pharmaceutically acceptable salt thereof, and a method for the treatment or prophylaxis of rabies and cancer using the same.